- Login
- Register & Subscribe
- Langue: EN FR DE
Finance, Grants, Deals
Ablynx and Spirogen to research ADCs
Monday 25 February 2013
Ablynx NV is to jointly research the potential of its therapeutic proteins conjugated to cytotoxic drugs developed by Spirogen Ltd, in a new research agreement announced by both parties on 25 February. The research collaboration is set to last for up to one year initially with an option to continue.
Location
Belgium
Domainex progresses funding round
Thursday 21 February 2013
The UK-based drug discovery company Domainex Ltd has announced plans to raise £1.5 million in new capital to support its kinase-based drug development programmes for cancer and a variety of inflammatory diseases. The round is being led by Longbow Capital LLP.
Location
United Kingdom
UCB in research deal with ConfometRX
Thursday 21 February 2013
UCB SA has signed an agreement with US-based ConfometRX Inc to discover new drugs to treat neurological diseases by targeting the G-protein coupled receptor (GPCR) family of proteins. GPCRs are the largest family of signaling proteins in the human genome.
Location
Belgium
Sphere Fluidics raises $2.5 million
Wednesday 20 February 2013
Sphere Fluidics Ltd of the UK, which has developed technology to analyse single cells, has raised $2.5 million in a Series A round from a syndicate led by 24Haymarket of London. The company’s technology comes from the chemistry department of Cambridge University.
Location
United Kingdom
MorphoSys, Heptares to work on antibody discovery
Wednesday 13 February 2013
MorphoSys AG and Heptares Therapeutics Ltd have entered into a collaboration to generate candidate antibody therapeutics targeting G protein-coupled receptors (GPCRs). The disease targets will be proposed by MorphoSys.
Location
Germany
e-Therapeutics raises £40 million in share placement
Monday 11 February 2013
e-Therapeutics Plc, which develops drugs that reach several optimized targets, has raised £40 million in a private placement with existing and new institutional investors. The placement is subject to existing shareholders waiving their preemption rights.
Location
United Kingdom
Venture money for the UK
Saturday 9 February 2013
Up to £50 million is expected to be made available for British life science following the setting up of a new fund that will seek to identify early-stage technologies with global commercialistion potential.
Location
United Kingdom
GSK increases stake in Indian subsidiary
Tuesday 5 February 2013
GlaxoSmithKline Plc has taken control of its publicly-listed consumer healthcare subsidiary in India in a transaction valued at about £568 million. As a consequence, it now owns 72.5% of GlaxoSmithKline Consumer Healthcare Ltd, up from 43.2% previously.
Location
United Kingdom
4-Antibody expands antibody alliance
Wednesday 30 January 2013
4-Antibody AG of Switzerland and its research partner, the Ludwig Institute for Cancer Research, have entered into a collaboration with Recepta Biopharma SA of Brazil to develop three antibody products for cancer.
Location
Switzerland
Abingworth debuts development firm
Tuesday 29 January 2013
The management of large pharmaceutical companies often struggle in deciding which products to bring forward into the expensive final stage of development. However, two venture capital companies have developed a way of ‘underwriting’ so that pharma can have more choices.
Location
United Kingdom
Select a News Category
Recent Appointments
Pascale Witz to head strategic development at Sanofi
Monday May 6 2013
Srinivas Akkaraju joins Sofinnova Ventures
Monday May 6 2013
Vicente Anido nominated to Nicox board
Monday May 6 2013
Jeremy Farrar named director of the Wellcome Trust
Monday May 6 2013
Harry Kirsch becomes CFO at Novartis
Monday May 6 2013